GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Charles Nock, MD

National Cancer Institute (NCI)

Intervention

vismodegib(drug)

Enrollment

44 enrolled

Eligibility

18 years · All sexes

Timeline

2010 – 2012

Study locations (9)

• University of California at Los Angeles, Los Angeles, California, United States
• University of California San Francisco, San Francisco, California, United States
• Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
• Dana-Farber Cancer Institute, Boston, Massachusetts, United States
• Henry Ford Hospital, Detroit, Michigan, United States
• Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
• University Hospitals Case Medical Center, Cleveland, Ohio, United States
• Cleveland Clinic Foundation, Cleveland, Ohio, United States
• University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06176066
  PH Sensitive MRI Based Resections of Glioblastoma
  University of California, Los Angeles
• RECRUITINGNCT05864976
  Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning
  Washington University School of Medicine
• ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05685004
  Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)
  TVAX Biomedical
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04922723
  Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma
  West Virginia University
• RECRUITINGPHASE1NCT05083754
  Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma
  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• ACTIVE NOT RECRUITINGPHASE1NCT04968366
  Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery
  Beijing Tiantan Hospital
• ACTIVE NOT RECRUITINGPHASE2NCT04574856
  Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma
  University of Michigan Rogel Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT04116411
  A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients
  Cecilia Soderberg-Naucler

See all trials for Giant cell glioblastoma →